digest
Short Summary
Main recommendation: Retatrutide, a new triple-agonist weight-loss drug from Eli Lilly that targets GLP-1, GIP, and glucagon receptors, is presented as the most effective weight-loss drug seen so far, though it remains in trials and is not yet available. The video cites a mid-stage trial in the New England Journal of Medicine showing about 24% average body weight loss at the highest dose over 48 weeks, compared with about 22% for Mounjaro (tirzepatide) over 72 weeks.
Key Points
- The trial, with over 300 patients with obesity (BMI of at least 30), reported an average of about 58 pounds lost over 48 weeks at the highest dose.
- Retatrutide also lowered blood pressure, with some patients able to stop their blood pressure medication, and most patients with prediabetes reached normal blood sugar levels by study end.
- Its common side effects resemble other GLP-1 drugs (nausea, vomiting, diarrhea, constipation) and worsened at higher doses, which is why treatment starts at lower doses.
- Less common side effects included skin tingling (paresthesia) in 7% of patients versus 1% on placebo, and one case of acute pancreatitis; heart rate rose until about 24 weeks, then declined.
- Eli Lilly is recruiting for a phase three trial, and the drug has no brand name yet.
- Separately, an oral weight-loss pill from Eli Lilly is expected to produce about 15% average weight loss, similar to Wegovy, with other oral GLP-1 pills coming from Novo Nordisk and Pfizer.
Details Worth Noting
- Concrete instructions: The video gives no step-by-step patient instructions. The only actionable point is that GLP-1 drugs are started at lower doses to let the body adjust and reduce side effects.
- Fatty liver disease: Dr. Hansen notes that results suggest retatrutide may help treat non-alcoholic fatty liver disease, which he says affects about one in four Americans, many unaware of it, and can progress to cirrhosis.
- Insulin resistance: Dr. Hansen states his view that many conditions, including fatty liver disease, heart disease, stroke, type 2 diabetes, high blood pressure, 13 obesity-related cancers, PCOS, and Alzheimer's, are linked to insulin resistance, so improving it may benefit these conditions too.
- Approval status: Mounjaro is currently FDA-approved only for type 2 diabetes, not weight loss, as of the video.
- Lab test: The video points viewers to another video for the single most important lab test to check insulin resistance, but names no test in the transcript.
Bottom Line
Retatrutide shows the strongest weight-loss results so far in a mid-stage trial, but it is still in development, with its benefits and side-effect profile being tested further in phase three.
